Enrollment for Helius Stroke Pivotal Study Exceeds Initial Target

Enrollment for Helius Stroke Pivotal Study Exceeds Initial Target

Summary: Helius Medical Technologies Inc. has surpassed initial enrollment targets for its stroke registrational program evaluating PoNS Therapy, a novel neuromodulation approach to improve gait and balance in stroke patients, aiming for FDA authorization in 2025. Key...
Costs for Drugs for Neurological Diseases Still on the Rise

Costs for Drugs for Neurological Diseases Still on the Rise

Summary: Out-of-pocket costs for branded drugs for neurological diseases, particularly for multiple sclerosis (MS), have significantly increased, with MS drugs seeing a 217% rise over nine years, despite cost reductions for medications with generic alternatives. Key...
Study: Product Improves Gait in Patients with Foot Drop, MS 

Study: Product Improves Gait in Patients with Foot Drop, MS 

Cionic announced data showcasing the impact of the FDA-cleared Cionic Neural Sleeve as assistive technology for individuals experiencing difficulty walking, including foot drop, due to multiple sclerosis (MS). The data from a pilot study was published in...
Study: Product Improves Gait in Patients with Foot Drop, MS 

3 Colorado Facilities Join Cionic Centers of Excellence Program

Cionic, the neurotech company that created the FDA-cleared Cionic Neural Sleeve, has announced three new additions to its national Centers of Excellence program, which provides leading neurological medical centers with exclusive training and access to utilize the...